KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Merck (MRK) Interest & Investment Income (2011 - 2013)

Merck (MRK) reported Interest & Investment Income of $57.0 million for Q1 2013, up 3.64% year-over-year from $55.0 million in Q1 2012, and up 3.64% on a QoQ basis from $55.0 million in Q4 2012.

Merck (MRK) has 3 years of Interest & Investment Income data on file, last reported at $57.0 million in Q1 2013.

  • Quarterly Interest & Investment Income rose 3.64% year-over-year to $57.0 million in Q1 2013, while the trailing twelve-month figure through Mar 2013 was $214.0 million (changed N/A YoY) and the FY2012 annual result came in at $1.8 billion, changed 0.0% from the prior year.
  • Interest & Investment Income rose to $57.0 million in Q1 2013 per MRK's latest filing, from $55.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $57.0 million in Q1 2013 and bottomed at $32.0 million in Q3 2011.
  • The 3-year median for Interest & Investment Income is $51.0 million (2012), against an average of $48.2 million.
  • The widest annual swing landed in 2012, when Interest & Investment Income surged 46.88%; it then increased 3.64% in 2013.
  • Tracing MRK's Interest & Investment Income over 3 years: stood at $43.0 million in 2011, then increased by 27.91% to $55.0 million in 2012, then advanced by 3.64% to $57.0 million in 2013.
  • Per Business Quant, the three latest MRK Interest & Investment Income figures stand at $57.0 million (Q1 2013), $55.0 million (Q4 2012), and $47.0 million (Q3 2012).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 229.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -645.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2013 57.00 Mn
Dec 31, 2012 55.00 Mn
Sep 30, 2012 47.00 Mn
Mar 31, 2012 55.00 Mn
Dec 31, 2011 43.00 Mn
Sep 30, 2011 32.00 Mn